Advertisement

Topics

Sirolimus Treatment for Refractory PRCA

2017-12-13 08:34:08 | BioPortfolio

Published on BioPortfolio: 2017-12-13T08:34:08-0500

Clinical Trials [426 Associated Clinical Trials listed on BioPortfolio]

Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa

The purpose of this study is to determine occurrence of pure red cell aplasia in a group of participants with chronic renal insufficiency and with resistance criteria to epoetin alfa treat...

A Study to Observe Patients Who Have Developed a More Severe Form of Anemia (Pure Red Cell Aplasia) Which is Associated With the Erythropoietin Treatment for Their Original Anemia

The purpose of this study is to investigate a possible relationship between antibodies to recombinant erythropoietin and the clinical course of Pure Red Cell Anemia (PRCA) in patients curr...

A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins

The purpose of this study is to record the number of patients with chronic renal disease who are receiving treatment with epoetin alfa or other recombinant erythropoietins who develop pure...

A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) and/or Antibodies to Erythropoietin While Receiving Epoetin Alfa or Another Recombinant Erythropoietin

The purpose of this study is to record the number of patients with chronic renal disease who are receiving treatment with epoetin alfa or other recombinant erythropoietins who develop pure...

Tacrolimus Treatment for Refractory PRCA

Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased. Cyclosporine and /or steroids are the fir...

PubMed Articles [16430 Associated PubMed Articles listed on BioPortfolio]

Progressive peripheral CD8 T lymphocytosis complicated by pure red cell aplasia following immunosuppressive therapy for thymoma-associated myasthenia gravis.

We herein report a unique case of type B2 thymoma-associated myasthenia gravis which was ameliorated by immunosuppressive therapy in combination with chemotherapy. However, the patient subsequently de...

Eltrombopag for the Treatment of of Refractory Pure Red Cell Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation.

Pure red cell aplasia (PRCS) is a well-recognized complication after allogeneic hematopoietic stem cell transplantation (HSCT). Many therapeutic options are available to treat this condition, includin...

Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.

Purpose Transplant recipients who develop cutaneous squamous cell carcinomas are at high risk for multiple subsequent skin cancers. Sirolimus has been shown to reduce the occurrence of secondary skin ...

Outcomes after cochlear implant provision in children with cochlear nerve hypoplasia or aplasia.

Cochlear nerve aplasia or hypoplasia is found in up to a half of patients with unilateral or bilateral hearing loss. There is an ongoing discussion regarding the indication of cochlear implants for he...

Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review.

Perivascular epithelioid cell tumor (PEComa) is a family of mesenchymal tumors. Conventional chemotherapy has little activity in this disease, but case reports are available on the activity of mammali...

Medical and Biotech [MESH] Definitions

Suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production.

A syndrome of congenital facial paralysis, frequently associated with abducens palsy and other congenital abnormalities including lingual palsy, clubfeet, brachial disorders, cognitive deficits, and pectoral muscle defects. Pathologic findings are variable and include brain stem nuclear aplasia, facial nerve aplasia, and facial muscle aplasia, consistent with a multifactorial etiology. (Adams et al., Principles of Neurology, 6th ed, p1020)

A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

Measurement of hearing based on the use of pure tones of various frequencies and intensities as auditory stimuli.

A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.

More From BioPortfolio on "Sirolimus Treatment for Refractory PRCA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial